Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from MaxCyte ( (MXCT) ).
On March 24, 2026, MaxCyte reported fourth-quarter 2025 revenue of $7.3 million, down 16% year-on-year, and full-year 2025 revenue of $33.0 million, a 15% decline, mainly due to headwinds from select SPL customers, including a 15% reduction in purchases and leases from its largest customer. Core revenue fell 22% in the quarter and 9% for the year, while SPL-related revenue decreased for 2025, but the company ended the year with 32 SPL agreements, $155.6 million in cash and investments, and an expanded installed base of 857 instruments.
Management highlighted cost-cutting progress that reduced annual cash burn by more than $16 million, streamlined operations and supported new product launches, positioning MaxCyte for long-term participation in the growing cell and gene therapy market. For 2026, the company guided for total revenue of $30–32 million, including $25–27 million in core revenue and $5 million from SPL programs, and expects at least $136 million in year-end cash, while anticipating revenue stabilization from key SPL customers in the second half of 2026 and growing support of up to four therapies in Phase III by year-end 2026.
The most recent analyst rating on (MXCT) stock is a Hold with a $0.77 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
MaxCyte, Inc. is a NASDAQ-listed cell-engineering company that provides enabling electroporation platform technologies and related assay services used in the discovery, development and commercialization of next-generation cell and gene therapies. The company generates revenue from instrument sales, disposables, licenses, assay services and Strategic Platform License (SPL) agreements with biopharma partners focused on cell and gene therapy programs.
Average Trading Volume: 1,073,876
Technical Sentiment Signal: Sell
Current Market Cap: $80.74M
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.